The Biostatistics and Clinical Core will provide the leadership and expertise needed to support the laboratory and clinical researeh ofthe 4 Projects of this SPORE grant. The Clinical component will be led by Dr. Prados, who will interact with Project leaders to develop clinical trials based upon laboratory investigations in Projects Three and Four in particular, as well as to discuss results in Projects One and Two that may lead to relevant biomarkers and potential stratification factors for future or potential clinical trials. The Clinical component will support the actual conduct of SPORE clinical trials, including providing clinicians, research nurses and data coordinators, and assist in all of the required regulatory reporting for those studies. Dr. Prados will support and facilitate the interactions of Project leaders with CTEP, cooperative groups, biopharmaceutical, and industry groups to obtain new therapeutic agents appropriate to the design of new studies that come from Projects Three and Four, as well as supporting the conduct of SPORE clinical trials to those groups as needed. The Biostatistical component wilt be led by Dr. Molinaro, who will interact on an ongoing basis with the individual leaders from all four Projects to assess the statistical needs of each. The Biostatistical component will provide: advice on the design of experimental and clinical studies, including calculating sample sizes and power;data analysis support (either by performing the analyses within the core or advising qualified personnel within the projects), including the use of appropriate statistical models and applications of statistical test;and, when necessary, the development of novel methods to help interpret results from experiments. Additionally, a member of the Biostatistical component will participate in regularly scheduled project meetings to provide statistical/bioinformatics input and assist in preparing the necessary materials for presentation and publication.
The primary aim of a SPORE grant is to support translational research that leads to clinical trials and ultimately improved outcome for patients. This Core will support the efforts of 4 Projects designed to study the biology, incidence, and epidemiology of brain tumors (high grade and low grade) using those results to translate into clinical trials. The Core will supply statistical and clinical leadership and input towards those efforts.
|Andersson, Ulrika; Wibom, Carl; Cederquist, Kristina et al. (2014) Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro Oncol 16:1333-40|
|Krishnamachari, Bhuma; Il'yasova, Dora; Scheurer, Michael E et al. (2014) A pooled multisite analysis of the effects of female reproductive hormones on glioma risk. Cancer Causes Control 25:1007-13|
|Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5|
|Sandstrom, Richard S; Foret, Michael R; Grow, Douglas A et al. (2014) Epigenetic regulation by chromatin activation mark H3K4me3 in primate progenitor cells within adult neurogenic niche. Sci Rep 4:5371|
|Davies, Jason M; Robinson, Aaron E; Cowdrey, Cynthia et al. (2014) Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. J Neurosurg 120:331-6|
|Lupo, Janine M; Nelson, Sarah J (2014) Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma. Semin Radiat Oncol 24:248-58|
|Ostrom, Quinn T; Bauchet, Luc; Davis, Faith G et al. (2014) The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol 16:896-913|
|Johnson, Brett E; Mazor, Tali; Hong, Chibo et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93|
|Lee, Seung-Tae; Bracci, Paige; Zhou, Mi et al. (2014) Interaction of allergy history and antibodies to specific varicella-zoster virus proteins on glioma risk. Int J Cancer 134:2199-210|
|Ohba, Shigeo; Mukherjee, Joydeep; See, Wendy L et al. (2014) Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res 74:4836-44|
Showing the most recent 10 out of 201 publications